A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Epimmune
With
Pharmexa A/S
Pharmexa-Epimmune
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
HIV-1 Infection
CD4 Tcell count \>350
HIV-1 RNA levels to \<400 copies
Negative HbsAg and anti-HCV antibody
You may not be if
Recent receipt of experimental HIV-1 vaccines
Recent use of immunomodulatory agents
Hypersensitivity or serious reactions to study vaccine components
Active opportunistic infections
Clareo Health | A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)
